Patient characteristics | |
Median age (range), years | 62 (51–83) |
Male, n (%) | 22 (88%) |
HCC etiology, n (%) | |
Hepatitis B (HBV) | 19 (76%) |
Hepatitis C (HCV) | 2 (8%) |
Alcoholic | 1 (4%) |
NASH | 2 (8%) |
Cryptogenic | 1 (4%) |
BCLC stage, n (%) | |
B | 4 (16%) |
C | 19 (76%) |
D | 2 (8%) |
Extrahepatic metastases, n (%) | 20 (80%) |
Vascular invasion, n (%) | 3 (12%) |
AFP ≥400 μg/L, n(%) | 11 (44%) |
CP Grade | |
A | 17 (68%) |
B | 6 (24%) |
C | 2 (8%) |
ALBI Grade | |
1 | 9 (36%) |
2 | 11 (44%) |
3 | 5 (20%) |
Baseline performance status | |
0–1 | 23 (92%) |
2 | 2 (8%) |
Prior ICI | |
Nivolumab | 19 (76%) |
Pembrolizumab | 5 (20%) |
Atezolizumab with bevacizumab | 1 (4%) |
Agents in combination with prior ICI | |
None | 21 (84%) |
Bevacizumab | 2 (8%) |
Capecitabine, oxaliplatin, irinotecan | 1 (4%) |
Cabozantinib | 1 (4%) |
Primary resistance to prior ICI | 12 (48%) |
Lines of systemic therapies prior to ipilimumab + anti-PD-1, n (%) | |
1 | 15 (60%) |
2 | 7 (28%) |
3 | 3 (12%) |
Therapies prior to any ICI, n (%) | |
Prior local treatment | 19 (76%) |
Curative surgical resection | 16 (64%) |
Radiotherapy | 5 (20%) |
TACE | 15 (60%) |
Prior systemic treatment | 10 (40%) |
Sorafenib | 7 (28%) |
Lenvatinib | 1 (4%) |
Enzalutamide | 1 (4%) |
PEG-BCT-100, oxaliplatin, capecitabine | 1 (4%) |
FGF401 | 1 (4%) |
AFP, alpha-fetoprotein; ALBI, Albumin-Bilirubin; BCLC, Barcelona clinic liver cancer; CP, Child-Pugh; HCC, hepatocellular carcinoma; ICI, immune checkpoint inhibitor; NASH, non-alcoholic steatohepatitis; PD-1, programmed cell death protein 1; TACE, Transarterial chemoembolization.